Publications

• Exploiting structural variability in the kinase back-pocket to modulate polypharmacology of TAM inhibitors.
  Eur J Med Chem Volume: 290 Page(s): 117561
  06/05/2025 Authors: Hopkins MD; Zhang D; Chen Z; McIver AL; Huelse JM; Mahajan JP; Lyu K; Yang X; Stashko MA; Smith B
• Immune-aging at diagnosis determines T-cell recovery in childhood leukemia survivors.
  NPJ Aging Volume: 11 Page(s): 39
  05/23/2025 Authors: Dhodapkar KM; Castellino S; Kapadia S; Azeem MI; Horvat A; Lawrence T; DeRyckere D; Dhodapkar MV
• Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas.
  Nat Commun Volume: 16 Page(s): 4114
  05/02/2025 Authors: Mumme HL; Huang C; Ohlstrom D; Bakhtiari M; Raikar SS; DeRyckere D; Qayed M; Castellino SM; Wechsler DS; Porter CC
• Discovery of Novel TYRO3/MERTK Dual Inhibitors.
  J Med Chem Volume: 68 Page(s): 8455 - 8470
  04/24/2025 Authors: Kong D; Zhao J; Huang D; Stashko MA; Yan D; Ding R; Guduru SKR; Zhou Y; Kania CE; Shelton Earp H
• UNC9426, a Potent and Orally Bioavailable TYRO3-Specific Inhibitor.
  J Med Chem Volume: 68 Page(s): 6665 - 6682
  03/27/2025 Authors: Kong D; Yang X; Judd S; Yan D; Springborn S; Stashko MA; Kidwell A; Huelse JM; Kireev D; Graham DK
• MERTK inhibition selectively activates a DC - T-cell axis to provide anti-leukemia immunity.
  Leukemia Volume: 38 Page(s): 2685 - 2698
  12/01/2024 Authors: Huelse JM; Bhasin SS; Jacobsen KM; Yim J; Thomas BE; Branella GM; Bakhtiari M; Chimenti ML; Baxter TA; Raikar SS
• MERTK Is a Potential Therapeutic Target in Ewing Sarcoma.
  Cancers (Basel) Volume: 16
  08/12/2024 Authors: Smart SK; Yeung TY; Santos MO; McSwain LF; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
  J Med Chem Volume: 67 Page(s): 5866 - 5882
  04/11/2024 Authors: Kong D; Tian Q; Chen Z; Zheng H; Stashko MA; Yan D; Earp HS; Frye SV; DeRyckere D; Kireev D
• TAM family kinases as therapeutic targets at the interface of cancer and immunity.
  Nat Rev Clin Oncol Volume: 20 Page(s): 755 - 779
  11/01/2023 Authors: DeRyckere D; Huelse JM; Earp HS; Graham DK
• Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
  Genome Med Volume: 15 Page(s): 83
  10/16/2023 Authors: Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS
• Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
  Nat Commun Volume: 14 Page(s): 6209
  10/05/2023 Authors: Mumme H; Thomas BE; Bhasin SS; Krishnan U; Dwivedi B; Perumalla P; Sarkar D; Ulukaya GB; Sabnis HS; Park SI
• Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
  J Control Release Volume: 361 Page(s): 470 - 482
  09/01/2023 Authors: Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H
• Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
  Pharm Res Volume: 40 Page(s): 2133 - 2146
  09/01/2023 Authors: Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E
• Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.
  Sci Rep Volume: 13 Page(s): 12556
  08/02/2023 Authors: Bhasin SS; Thomas BE; Summers RJ; Sarkar D; Mumme H; Pilcher W; Emam M; Raikar SS; Park SI; Castellino SM
• Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia.
  Cancer Res Commun Volume: 3 Page(s): 1248 - 1259
  07/01/2023 Authors: Pillsbury CE; Dougan J; Rabe JL; Fonseca JA; Zhou C; Evans AN; Abukharma H; Ichoku O; Gonzalez-Flamenco G; Park SI
• Targeting a positive feedback loop of MERTK and STAT3 during macrophage differentiation may provide anti-tumor immune function
  Volume: 83
  04/01/2023 Authors: Yan D; Huelse JM; Bhasin SS; Bhasin M; DeRyckere D; Graham DK
• Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.
  bioRxiv
  03/15/2023 Authors: Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Costanza E; Uricoli B
• Machine learning classifier approaches for predicting response to RTK-type-III inhibitors demonstrate high accuracy using transcriptomic signatures and ex vivo data.
  Bioinform Adv Volume: 3 Page(s): vbad034
  01/01/2023 Authors: Ferrato MH; Marsh AG; Franke KR; Huang BJ; Kolb EA; DeRyckere D; Grahm DK; Chandrasekaran S; Crowgey EL
• Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
  Cancers (Basel) Volume: 14
  12/13/2022 Authors: Summers RJ; Jain J; Vasileiadi E; Smith B; Chimenti ML; Yeung TY; Kelvin J; Wang X; Frye SV; Earp HS
• MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
  J Clin Invest Volume: 132
  08/01/2022 Authors: Yan D; Huelse JM; Kireev D; Tan Z; Chen L; Goyal S; Wang X; Frye SV; Behera M; Schneider F
• MERTK INHIBITIOR, MRX-2843, IS A POTENTIAL NOVEL THERAPY IN PEDIATRIC BONE SARCOMAS
  Volume: 69
  06/01/2022 Authors: Smart S; Yeung T; Wang X; Frye S; Earp HS; Graham D; DeRyckere D
• ENRICHMENT OF HIGH-RISK INNATE IMMUNE CELLS IN HISPANIC AND BLACK CHILDREN WITH B-ALL
  Volume: 69
  06/01/2022 Authors: Gilbert J; Sabnis H; Radzievski R; Doxie D; DeRyckere D; Castellino S; Dhodapkar K
• Association of race/ethnicity with innate immune tumor microenvironment of children with B-acute lymphoblastic leukemia.
  J Immunother Cancer Volume: 10
  06/01/2022 Authors: Gilbert JR; Sabnis HS; Radzievski R; Doxie DB; DeRyckere D; Castellino SM; Dhodapkar K
• Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.
  Nat Commun Volume: 13 Page(s): 1157
  03/03/2022 Authors: Lee M; Hamilton JAG; Talekar GR; Ross AJ; Michael L; Rupji M; Dwivedi B; Raikar SS; Boss J; Scharer CD
• Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening.
  Adv Mater Volume: 34 Page(s): e2108084
  03/01/2022 Authors: O'Melia MJ; Mulero-Russe A; Kim J; Pybus A; DeRyckere D; Wood L; Graham DK; Botchwey E; Garca AJ; Thomas SN
• Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer.
  Cancers (Basel) Volume: 13
  11/11/2021 Authors: Yan D; Earp HS; DeRyckere D; Graham DK
• Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577].
  Pharmacol Ther Volume: 225 Page(s): 107822
  09/01/2021 Authors: Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
• UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
  Eur J Med Chem Volume: 220 Page(s): 113534
  08/05/2021 Authors: Zheng H; Zhao J; Li B; Zhang W; Stashko MA; Minson KA; Huey MG; Zhou Y; Earp HS; Kireev D
• MEK INHIBITION OVERCOMES STROMAL CELL-MEDIATED RESISTANCE TO MRX-2843, A DUAL MERTK/FLT3 INHIBITOR
  Volume: 68 Page(s): S10 - S10
  06/01/2021 Authors: Fridlyand D; Minson K; Vasileiadi E; Huey M; Wang X; Frye S; Earp HS; Graham D; DeRyckere D
• PRECISION NANOMEDICINE: A NOVEL THERAPEUTIC APPROACH FOR PEDIATRIC LEUKEMIA
  Volume: 68 Page(s): S44 - S44
  06/01/2021 Authors: Jain J; Kelvin J; Costanza E; DeRyckere D; Dreaden E
• MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
  JCI Insight Volume: 5
  12/03/2020 Authors: Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS
• Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML
  Volume: 136
  11/05/2020 Authors: Thomas BE; Perumalla P; Bhasin SS; Sarkar D; Dwivedi B; Park SI; DeRyckere D; Henry CJ; Raikar SS; Porter CC
• MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
  Pharmacol Ther Volume: 213 Page(s): 107577
  09/01/2020 Authors: Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
• Risk-associated alterations in marrow T cells in pediatric leukemia.
  JCI Insight Volume: 5
  08/20/2020 Authors: Bailur JK; McCachren SS; Pendleton K; Vasquez JC; Lim HS; Duffy A; Doxie DB; Kaushal A; Foster C; DeRyckere D
• MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib
  Volume: 80
  08/01/2020 Authors: Yan D; Huelse J; Parker R; Tan Z; Wang X; Frye S; Earp HS; DeRyckere D; Graham DK
• MERTK and ROCK inhibitors mediate synergistic AML cell death and enhance therapeutic activity in combination with cytotoxic chemotherapy
  Volume: 80
  08/01/2020 Authors: Barnes DE; Wang X; Frye S; Earp HS; DeRyckere D; Barnes DK
• BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway.
  Oncogene Volume: 39 Page(s): 2305 - 2327
  03/01/2020 Authors: Green AL; DeSisto J; Flannery P; Lemma R; Knox A; Lemieux M; Sanford B; O'Rourke R; Ramkissoon S; Jones K
• Correction: BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway.
  Oncogene Volume: 39 Page(s): 2641
  03/01/2020 Authors: Green AL; DeSisto J; Flannery P; Lemma R; Knox A; Lemieux M; Sanford B; O'Rourke R; Ramkissoon S; Jones K
• Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology.
  J Am Chem Soc Volume: 141 Page(s): 15700 - 15709
  10/02/2019 Authors: Da C; Zhang D; Stashko M; Vasileiadi E; Parker RE; Minson KA; Huey MG; Huelse JM; Hunter D; Gilbert TSK
• MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia
  Volume: 79
  07/01/2019 Authors: Summers RJ; Minson KA; Vasileiadi E; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• TYRO3 is a potential therapeutic target in pediatric acute myeloid leukemia
  Volume: 79
  07/01/2019 Authors: Smart SK; Rupji M; Dwivedi B; Kowalski J; DeRyckere D; Graham DK
• Stromal cell activation of MAPK signaling pathways mediates resistance to MERTK inhibition in acute myeloid leukemia
  Volume: 79
  07/01/2019 Authors: Minson KA; Vasileiadi E; Huey MG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer
  Volume: 79
  07/01/2019 Authors: Yan D; Huelse J; Parker R; Wang X; Frye SV; Earp HS; DeRyckere D; Graham D
• Combined MERTK and ROCK1/2 inhibition as a potential therapeutic strategy for AML
  Volume: 79
  07/01/2019 Authors: Barnes DE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
  Mol Cancer Ther Volume: 18 Page(s): 278 - 288
  02/01/2019 Authors: Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X
• MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members.
  Clin Cancer Res Volume: 24 Page(s): 6523 - 6535
  12/15/2018 Authors: Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
  Cancers (Basel) Volume: 10
  11/29/2018 Authors: Smart SK; Vasileiadi E; Wang X; DeRyckere D; Graham DK
• Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
  J Med Chem Volume: 61 Page(s): 10242 - 10254
  11/21/2018 Authors: Zhao J; Zhang D; Zhang W; Stashko MA; DeRyckere D; Vasileiadi E; Parker RE; Hunter D; Liu Q; Zhang Y
• MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
  JCI Insight Volume: 3
  11/02/2018 Authors: Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS
• MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
  Mol Cancer Ther Volume: 17 Page(s): 2297 - 2308
  11/01/2018 Authors: McDaniel NK; Cummings CT; Iida M; Hlse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB
• MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia
  Volume: 78
  10/01/2018 Authors: Summers RJ; Minson KA; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• MRX-2843, a dual MERTK/FLT3 inhibitor enabled by the NCI Chemical Biology Consortium (CBC) entering Phase 1 clinical trials
  Volume: 256
  08/19/2018 Authors: Wang X; DeRyckere D; Kireev D; Graham D; Earp HS; Frye S
• BONE MARROW STROMAL CELL MEDIATED RESISTANCE TO MERTK INHIBITION IN AML
  Volume: 65
  06/01/2018 Authors: Minson K; Huey M; Vasileiadi E; Perez I; Wang X; Frye S; Earp HS; DeRyckere D; Graham D
• The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis.
  J Thromb Haemost Volume: 16 Page(s): 352 - 363
  02/01/2018 Authors: Branchford BR; Stalker TJ; Law L; Acevedo G; Sather S; Brzezinski C; Wilson KM; Minson K; Lee-Sherick AB; Davizon-Castillo P
• MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents
  Volume: 17
  01/01/2018 Authors: McDaniel NK; Cummings CT; Brand TM; Iida M; Hulse J; Pearson HE; Orbuch RA; Ondracek OJ; Davies KD; Gill P
• Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Myeloid Leukemia
  Volume: 130
  12/07/2017 Authors: Minson KA; Huey MG; Qiu A; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
• UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models (vol 23, pg 1481, 2017)
  CLINICAL CANCER RESEARCH Volume: 23 Page(s): 3971 - 3972
  07/15/2017 Authors: DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM
• MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR
  Volume: 77
  07/01/2017 Authors: Yan D; Wang X; Frye SV; Earp SH; DeRyckere D; Graham DK
• MERTK is a Potential Therapeutic Target in Early Thymic Precursor Acute Lymphoblastic Leukemia
  Volume: 64 Page(s): S3 - S3
  06/01/2017 Authors: Summers R; Minson K; Wang X; Frye S; Earp HS; DeRyckere D; Graham D
• MERTK inhibition in the leukemia microenvironment promotes a therapeutic immune response to acute lymphoblastic leukemia
  Volume: 198
  05/01/2017 Authors: Jacobsen KM; Lee-Sherick AB; Huey MG; Page LS; Zhang W; Wang X; Fyre SV; Earp HS; Jordan CT; DeRyckere D
• UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.
  Clin Cancer Res Volume: 23 Page(s): 1481 - 1492
  03/15/2017 Authors: DeRyckere D; Lee-Sherick AB; Huey MG; Hill AA; Tyner JW; Jacobsen KM; Page LS; Kirkpatrick GG; Eryildiz F; Montgomery SA
• Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors.
  ChemMedChem Volume: 12 Page(s): 207 - 213
  02/03/2017 Authors: McIver AL; Zhang W; Liu Q; Jiang X; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Machius M; DeRyckere D
• The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
  J Cell Signal (Los Angel) Volume: 2
  01/01/2017 Authors: Minson KA; DeRyckere D; Graham DK
• Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.
  ACS Med Chem Lett Volume: 7 Page(s): 1044 - 1049
  12/08/2016 Authors: Wang X; Liu J; Zhang W; Stashko MA; Nichols J; Miley MJ; Norris-Drouin J; Chen Z; Machius M; DeRyckere D
• Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
  Oncogene Volume: 35 Page(s): 6270
  12/01/2016 Authors: Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C
• Targeting the TAM Receptors in Leukemia.
  Cancers (Basel) Volume: 8
  11/08/2016 Authors: Huey MG; Minson KA; Earp HS; DeRyckere D; Graham DK
• STROMAL CELL GAS6 PROTECTS LEUKEMIA CELLS FROM MERTK INHIBITION
  Volume: 63 Page(s): S26 - S26
  06/01/2016 Authors: Huey M; Hill A; Minson K; Wang X; Frye S; Earp S; DeRyckere D; Graham D
• The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.
  JCI Insight Volume: 1 Page(s): e85630
  03/01/2016 Authors: Minson KA; Smith CC; DeRyckere D; Libbrecht C; Lee-Sherick AB; Huey MG; Lasater EA; Kirkpatrick GD; Stashko MA; Zhang W
• MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
  PLoS One Volume: 11 Page(s): e0165107
  01/01/2016 Authors: Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV
• Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
  Mol Cancer Ther Volume: 14 Page(s): 2014 - 2022
  09/01/2015 Authors: Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
• MRX2843, A NOVEL DUAL MERTK & FLT3 INHIBITOR WITH ACTIVITY AGAINST RESISTANCE-CONFERRING FLT3 MUTATIONS IN ACUTE MYELOID LEUKEMIA
  Volume: 62 Page(s): 27 - 27
  06/01/2015 Authors: Minson K; Smith C; Lee-Sherick A; Libbrecht C; DeRyckere D; Lasater E; Hill A; Wang X; Frye S; Earp HS
• Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.
  Oncotarget Volume: 6 Page(s): 6722 - 6736
  03/30/2015 Authors: Lee-Sherick AB; Zhang W; Menachof KK; Hill AA; Rinella S; Kirkpatrick G; Page LS; Stashko MA; Jordan CT; Wei Q
• Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
  Clin Cancer Res Volume: 21 Page(s): 1360 - 1372
  03/15/2015 Authors: Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V
• UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia
  Volume: 124
  12/06/2014 Authors: DeRyckere D; Lee-Sherick AB; Hill AA; Page L; Wang X; Frye SV; Earp HS; Graham DK
• The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.
  Nat Rev Cancer Volume: 14 Page(s): 769 - 785
  12/01/2014 Authors: Graham DK; DeRyckere D; Davies KD; Earp HS
• Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.
  Oncotarget Volume: 5 Page(s): 10434 - 10445
  11/15/2014 Authors: Cummings CT; Linger RMA; Cohen RA; Sather S; Kirkpatrick GD; Davies KD; DeRyckere D; Earp HS; Graham DK
• UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia
  Volume: 50 Page(s): 114 - 114
  11/01/2014 Authors: Graham D; DeRyckere D; Wang X; Hill AA; Zhang W; Frye SV; Earp HS
• Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia
  Volume: 74
  10/01/2014 Authors: DeRyckere DA; Hill AA; Wang X; Zhang W; Stashko MA; Sather S; Cummings C; Kireev D; Janzen WP; Frye SV
• A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition
  Volume: 74
  10/01/2014 Authors: Newton TP; Cummings CT; Kirkpatrick GD; Hinz TK; DeRyckere D; Zhang W; Wang X; Frye S; Earp HS; Heasley L
• Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer
  Volume: 74
  10/01/2014 Authors: Cummings CT; Davies KD; Carrico J; DeRyckere D; Zhang W; Wang X; Frye S; Earp HS; Graham DK
• Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines
  Volume: 74
  10/01/2014 Authors: Teodorovic LS; Carrico J; DeRyckere D; Zhang W; Wang X; Frye S; Eckhardt SG; Earp HS; Graham DK
• Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer
  Volume: 74
  10/01/2014 Authors: Jacobsen KM; DeRyckere D; Zhang W; Wang X; Frye SV; Earp HS; Graham DK
• A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma
  Volume: 74
  10/01/2014 Authors: Earp HS; Darr D; Zimmermann A; Clark K; Sharpless NE; Bergmeier W; Zhang W; Wang X; DeRyckere D; Frye S
• A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples
  Volume: 74
  10/01/2014 Authors: Sherick AL; Menachof K; Hill A; Rinella S; DeRyckere D; Liu J; Wang X; Frye S; Earp HS; Graham D
• MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia
  Volume: 74
  10/01/2014 Authors: Graham DK; DeRyckere D; Lee-Sherick A; Hill AA; Minson K; Xiaodong W; Zhang W; Liu J; Frye S; Earp HS
• UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.
  J Med Chem Volume: 57 Page(s): 7031 - 7041
  08/28/2014 Authors: Zhang W; DeRyckere D; Hunter D; Liu J; Stashko MA; Minson KA; Cummings CT; Lee M; Glaros TG; Newton DL
• A NOVEL SMALL MOLECULE INHIBITOR OF THE GAS6/TAM PATHWAY, IN COMBINATION WITH ADP/P2Y ANTAGONISTS, MEDIATE SYNERGISTIC INHIBITION OF PLATELET AGGREGATION AND DECREASES ARTERIAL & VENOUS THROMBOSIS
  Volume: 89 Page(s): E7 - E8
  06/01/2014 Authors: Branchford BR; Law L; Acevedo G; Brzezinski C; Sather S; Brodsky G; DeRyckere D; Zhang W; Earp HS; Frye S
• PRE-CLINICAL EVALUATION OF NOVEL FLT3 INHIBITORS EFFECTIVE IN FLT3-ITD ACUTE MYELOID LEUKEMIA
  Volume: 61 Page(s): S52 - S52
  05/01/2014 Authors: Minson K; Sherick AL; DeRyckere D; Wang X; Frye S; Earp HS; Graham D
• Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.
  J Med Chem Volume: 56 Page(s): 9683 - 9692
  12/12/2013 Authors: Zhang W; Zhang D; Stashko MA; DeRyckere D; Hunter D; Kireev D; Miley MJ; Cummings C; Lee M; Norris-Drouin J
• Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.
  J Med Chem Volume: 56 Page(s): 9693 - 9700
  12/12/2013 Authors: Zhang W; McIver AL; Stashko MA; DeRyckere D; Branchford BR; Hunter D; Kireev D; Miley MJ; Norris-Drouin J; Stewart WM
• Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice Fro Arterial and Venous Thrombosis In Vivo
  Volume: 122
  11/15/2013 Authors: Acevedo G; Branchford BR; Brzezinski C; Sather S; Brodsky G; DeRyckere D; Zhang W; Liu J; Earp HS; Wang X
• Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma
  Volume: 122
  11/15/2013 Authors: Christoph S; Maag S; DeRyckere D; Graham DK; Frye SV; Earp HS; Liu J; Yang C; Zhang W; Wang X
• Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists
  Volume: 122
  11/15/2013 Authors: Acevedo G; Branchford BR; Law L; Brzezinski C; Sather S; Brodsky G; DeRyckere D; Zhang W; Earp HS; Frye SV
• Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia
  Volume: 122
  11/15/2013 Authors: DeRyckere D; Wang X; Hill AA; Zhang W; Stashko MA; Sather S; Cummings CE; Janzen WP; Frye SV; Earp HS
• Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.
  Oncogene Volume: 32 Page(s): 5359 - 5368
  11/14/2013 Authors: Lee-Sherick AB; Eisenman KM; Sather S; McGranahan A; Armistead PM; McGary CS; Hunsucker SA; Schlegel J; Martinson H; Cannon C
• UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
  Mol Cancer Ther Volume: 12 Page(s): 2367 - 2377
  11/01/2013 Authors: Christoph S; Deryckere D; Schlegel J; Frazer JK; Batchelor LA; Trakhimets AY; Sather S; Hunter DM; Cummings CT; Liu J
• Molecular pathways: MERTK signaling in cancer.
  Clin Cancer Res Volume: 19 Page(s): 5275 - 5280
  10/01/2013 Authors: Cummings CT; Deryckere D; Earp HS; Graham DK
• Preclinical evaluation of UNC1062, a novel small molecule mer inhibitor for the treatment of multiple myeloma
  Volume: 36 Page(s): 145 - 145
  10/01/2013 Authors: Christoph S; Maag S; Deryckere D; Graham DK; Frye S; Earp HS; Liu J; Yang C; Zhang W; Wang X
• Inhibition of MerTK in tumor infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer
  Volume: 11
  10/01/2013 Authors: Jacobsen KM; Cook RS; DeRyckere D; Stanford J; Hunter DM; Wang X; Frye S; Graham DK; Earp HS
• Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.
  J Vis Exp Page(s): e50720
  09/18/2013 Authors: Christoph S; Lee-Sherick AB; Sather S; DeRyckere D; Graham DK
• Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.
  Blood Volume: 122 Page(s): 1599 - 1609
  08/29/2013 Authors: Linger RMA; Lee-Sherick AB; DeRyckere D; Cohen RA; Jacobsen KM; McGranahan A; Brando LN; Winges A; Sawczyn KK; Liang X
• MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
  J Clin Invest Volume: 123 Page(s): 3231 - 3242
  08/01/2013 Authors: Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE
• Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
  Oncogene Volume: 32 Page(s): 3420 - 3431
  07/18/2013 Authors: Linger RMA; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DHG; Lu X; Barn AE; Franklin WA; Merrick DT
• UNC1062, a new and potent Mer inhibitor.
  Eur J Med Chem Volume: 65 Page(s): 83 - 93
  07/01/2013 Authors: Liu J; Zhang W; Stashko MA; Deryckere D; Cummings CT; Hunter D; Yang C; Jayakody CN; Cheng N; Simpson C
• Inhibition of the Gas6/Mer pathway with novel compounds recapitulates the antithrombotic phenotype of Gas6-/- or Mer-/- mice in arterial and venous thrombosis models
  Volume: 11 Page(s): 344 - 345
  07/01/2013 Authors: Branchford BR; Law L; Sather S; Brodsky G; DeRyckere D; Earp SH; Wang X; Frye S; Graham DK; Di Paola JA
• MERTK receptor tyrosine kinase is a therapeutic target in melanoma.
  J Clin Invest Volume: 123 Page(s): 2257 - 2267
  05/01/2013 Authors: Schlegel J; Sambade MJ; Sather S; Moschos SJ; Tan A-C; Winges A; DeRyckere D; Carson CC; Trembath DG; Tentler JJ
• Bioluminescence imaging for assessment of drug efficacy in human leukemia cell lines: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission
  Volume: 54 Page(s): 6 - 6
  02/01/2013 Authors: Christoph S; Schlegel J; Alvarez-Calderon F; Kim YM; Brandao LN; DeRyckere D; Graham DK
• Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia.
  Blood Cancer J Volume: 3 Page(s): e101
  01/25/2013 Authors: Brandao LN; Winges A; Christoph S; Sather S; Migdall-Wilson J; Schlegel J; McGranahan A; Gao D; Liang X; Deryckere D
• Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission.
  J Hematol Oncol Volume: 6 Page(s): 10
  01/23/2013 Authors: Christoph S; Schlegel J; Alvarez-Calderon F; Kim Y-M; Brandao LN; DeRyckere D; Graham DK
• Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia
  Volume: 120
  11/16/2012 Authors: Lee-Sherick AB; Menachof K; Eisenman KM; McGranahan A; McGary C; Hunsucker SA; Schlegel J; Armistead PM; Liang X; Kireev D
• UNC569 as a novel small molecule Mer receptor tyrosine kinase inhibitor for the treatment of ALL
  Volume: 35 Page(s): 185 - 185
  10/01/2012 Authors: Christoph S; DeRyckere D; Sather S; Wang X; Kireev D; Janzen W; Liu J; Yang C; Simpson C; Norris-Drouin J
• Retraction. Linger RMA, DeRyckere D, Brandao L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 2009;114(13):2678-2687.
  Blood Volume: 120 Page(s): 1533
  08/16/2012
• Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
  Invest New Drugs Volume: 30 Page(s): 468 - 479
  04/01/2012 Authors: Macy ME; DeRyckere D; Gore L
• Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.
  ACS Med Chem Lett Volume: 3 Page(s): 129 - 134
  02/09/2012 Authors: Liu J; Yang C; Simpson C; Deryckere D; Van Deusen A; Miley MJ; Kireev D; Norris-Drouin J; Sather S; Hunter D
• Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus.
  PLoS One Volume: 7 Page(s): e31635
  01/01/2012 Authors: Migdall-Wilson J; Bates C; Schlegel J; Brando L; Linger RMA; DeRyckere D; Graham DK
• UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL
  Volume: 118 Page(s): 1111 - 1112
  11/18/2011 Authors: Christoph S; DeRyckere D; Sather S; Wang X; Kireev D; Janzen W; Liu J; Yang C; van Deusen A; Simpson C
• Mer Receptor Tyrosine Kinase Is Over-Expressed In and Contributes to Oncogenesis In Acute Myeloid Leukemia
  Volume: 118 Page(s): 607 - 608
  11/18/2011 Authors: Lee-Sherick AB; Eisenman KM; Sather S; DeRyckere D; Schlegel J; Graham DK
• Imer Blocks Phosphorylation of the beta(3) Integrin, Decreasing Platelet Activation Responses and Protecting Mice From Arterial Thrombosis
  Volume: 118 Page(s): 90 - 90
  11/18/2011 Authors: Branchford BR; Sather S; Brodsky G; White-Adams TC; DeRyckere D; Neeves KB; Wilson KM; Lentz SR; Graham DK; Di Paola JA
• A novel splice variant of the mer receptor tyrosine kinase functions as an inhibitor of the Gas6/TAM signaling pathway and decreases platelet activation responses
  Volume: 9 Page(s): 43 - 43
  07/01/2011 Authors: Branchford BR; Sather S; Brodsky G; White-Adams T; DeRyckere D; Neeves K; Graham D; Paola JD
• A novel splice variant of the Mer receptor tyrosine kinase functions as an inhibitor of the Gas6/TAM signaling pathway and decreases platelet activation responses
  Volume: 17 Page(s): 564 - 564
  05/01/2011 Authors: Branchford B; Sather S; Brodsky G; White-Adams T; Deryckere D; Neeves K; Graham D; Di Paola J
• Identification of metabolic markers of acute myeloid leukemia in MLL-AF9 transgenic mice
  Volume: 8
  12/01/2009 Authors: DeRyckere D; Gore L; Gardner LA; Merz AL; Serkova N
• Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.
  Volume: 114 Page(s): 2678 - 2687
  09/24/2009 Authors: Linger RMA; DeRyckere D; Brando L; Sawczyn KK; Jacobsen KM; Liang X; Keating AK; Graham DK
• (PLATFORM 303A) THE MER RECEPTOR TYROSINE KINASE IS A NOVEL ALL THERAPEUTIC TARGET
  Volume: 52 Page(s): 696 - 696
  06/01/2009 Authors: Linger RMA; DeRyckere D; Brandao L; Sawezyn K; Jacobsen KM; Keating AK; Graham DK
• EVALUATION OF THE ANTI-TUMOR ACTIVITY OF VANDETANIB IN PEDIATRIC ACUTE LEUKEMIAS IN VITRO
  PEDIATRIC BLOOD & CANCER Volume: 52 Page(s): 714 - 714
  06/01/2009 Authors: Macy M; DeRyckere D; Gore L
• Synergistic Killing of E2A-PBX1(+) B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition.
  Volume: 112 Page(s): 982 - 982
  11/16/2008 Authors: Linger RMA; DeRyckere D; Brandao L; Sawczyn KK; Keating AK; Graham DK
• The role of vascular endothelial growth factor signaling in pediatric acute leukemia
  MOLECULAR CANCER THERAPEUTICS Volume: 6 Page(s): 3597S - 3597S
  12/01/2007 Authors: Macy M; Gore L; DeRyckere D
• Preclinical development of histone deacetylase inhibitors for the treatment of pediatric acute leukemia
  MOLECULAR CANCER THERAPEUTICS Volume: 6 Page(s): 3379S - 3379S
  12/01/2007 Authors: DeRyckere D; Gore L
• In vitro evaluation of the antitumor activity of vandetanib in pediatric acute leukemias
  Volume: 110 Page(s): 262A - 263A
  11/16/2007 Authors: Macy ME; DeRyckere D; Gore L
• Pre-clinical development of suberoylanilide hydroxamic acid (SAHA, Vorinostat (TM)) for the treatment of pediatric acute leukemias.
  Volume: 108 Page(s): 645A - 645A
  11/16/2006 Authors: DeRyckere D; Garrington TP; Gore L
• Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.
  Oncogene Volume: 25 Page(s): 6092 - 6100
  10/05/2006 Authors: Keating AK; Salzberg DB; Sather S; Liang X; Nickoloff S; Anwar A; Deryckere D; Hill K; Joung D; Sawczyn KK
• Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer receptor tyrosine kinase.
  Volume: 106 Page(s): 736A - 736A
  11/16/2005 Authors: Salzberg DB; Keating AK; Anwar A; Sawczyn K; Hill K; Sather S; Park J; DeRyckere D; Everett D; Graham DK
• E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo.
  J Immunol Volume: 175 Page(s): 647 - 655
  07/15/2005 Authors: DeRyckere D; DeGregori J
• Characterization of transcriptional regulation during negative selection in vivo.
  J Immunol Volume: 171 Page(s): 802 - 811
  07/15/2003 Authors: DeRyckere D; Mann DL; DeGregori J
• Identification and characterization of transcription factor target genes using gene-targeted mice.
  Methods Volume: 26 Page(s): 57 - 75
  01/01/2002 Authors: DeRyckere D; DeGregori J
• Structure and function of Cdc6/Cdc18: implications for origin recognition and checkpoint control.
  Mol Cell Volume: 6 Page(s): 637 - 648
  09/01/2000 Authors: Liu J; Smith CL; DeRyckere D; DeAngelis K; Martin GS; Berger JM
• A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection.
  Cell Growth Differ Volume: 10 Page(s): 829 - 838
  12/01/1999 Authors: Zhu JW; DeRyckere D; Li FX; Wan YY; DeGregori J
• The role of nucleotide binding and hydrolysis in the function of the fission yeast cdc18(+) gene product.
  Genetics Volume: 151 Page(s): 1445 - 1457
  04/01/1999 Authors: DeRyckere D; Smith CL; Martin GS
• Gene conversion in Neisseria gonorrhoeae: evidence for its role in pilus antigenic variation.
  Proc Natl Acad Sci U S A Volume: 89 Page(s): 5366 - 5370
  06/15/1992 Authors: Zhang QY; DeRyckere D; Lauer P; Koomey M